[HTML][HTML] Tumor quantification in clinical positron emission tomography

B Bai, J Bading, PS Conti - Theranostics, 2013 - ncbi.nlm.nih.gov
Positron emission tomography (PET) is used extensively in clinical oncology for tumor
detection, staging and therapy response assessment. Quantitative measurements of tumor …

[HTML][HTML] Glucose fluxes in glycolytic and oxidative pathways detected in vivo by deuterium magnetic resonance spectroscopy reflect proliferation in mouse …

RV Simões, RN Henriques, BM Cardoso… - NeuroImage: Clinical, 2022 - Elsevier
Objectives Glioblastoma multiforme (GBM), the most aggressive glial brain tumors, can
metabolize glucose through glycolysis and mitochondrial oxidation pathways. While specific …

Mathematical Models for FDG Kinetics in Cancer: A Review

S Sommariva, G Caviglia, G Sambuceti, M Piana - Metabolites, 2021 - mdpi.com
Compartmental analysis is the mathematical framework for the modelling of tracer kinetics in
dynamical Positron Emission Tomography. This paper provides a review of how …

FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC …

AR Baudy, T Dogan, JE Flores-Mercado, KP Hoeflich… - EJNMMI research, 2012 - Springer
Background The BRAF inhibitor, vemurafenib, has recently been approved for the treatment
of metastatic melanoma in patients harboring BRAF V600 mutations. Currently, dual BRAF …

Radiolabeling and Biological Evaluation of Novel 99mTc-Nitrido and 99mTc-Oxo Complexes with 4-Methoxy-L-Phenylalanine Dithiocarbamate for Tumor Imaging

G Yin, Q Ruan, Y Jiang, J Zhang - Pharmaceutics, 2022 - mdpi.com
To develop novel radiolabeled amino acid tumor imaging agents, 4-methoxy-l-
phenylalanine dithiocarbamate (MOPADTC) was synthesized successfully, and two kinds of …